It is my pleasure to welcome you to the Annual Report 2025 – a year characterized by sustained momentum, disciplined execution of the One Lonza strategy, and strong top line and profitable growth. Throughout the year, the Board of Directors focused on providing the company with strategic direction, strengthened governance and enhanced the board’s mix of skills, expertise and effectiveness.
2025 was a strong year for the One Lonza team. In my first full year as CEO, we delivered significant revenue growth, expanded profitability and made tangible progress on our transformation journey. We executed our existing business with rigor and, at the same time, continued to lay the foundations for future growth.
Sales in CHF
CORE EBITDA in CHF
CORE EBITDA margin in %
ROIC in %
Employees (Full-time equivalent)
Small3 and large4 molecules
Global development and manufacturing sites
Brands
Trademark filings
Active patent families
Based on Lonza continuing operations excluding Capsules & Health Ingredients business that is classified as discontinued operations.
Including Capsules & Health Ingredients colleagues
Including active pharmaceutical ingredients (API), highly potent API (HPAPI), dosage form and delivery systems and particle engineering.
Including mammalian, microbial, bioconjugates, drug product services and cell and gene therapy products (early development services are included for pre-clinical molecules only).
Our focus on high‑quality assets and disciplined cost management delivered strong growth and improved profitability in 2025. Driven by sustained customer demand, the progress in our growth project portfolio is the foundation for future profitable growth. Guided by a balanced capital allocation approach, we are committed to delivering long‑term value for our shareholders, our customers and the patients they serve.
In 2025, we have continued to push progress in elevating operational excellence and further improving our discipline in executing CapEx investments. I wish Jason every success as he takes over the leadership of Group Operations and I focus on my new role as Chief Quality Officer.
Maria has laid a strong foundation for execution excellence in Group Operations, and I am looking forward to supporting Lonza's ambitious growth trajectory by leading this important function into its next chapter.
Sustainability is an integral part of our strategy and a long-standing commitment at Lonza. We remain focused on ensuring sustainability remains a competitive advantage that secures long-term value for our business, our customers and all our stakeholders. We are proud to have been awarded the EcoVadis Gold medal for our sustainability efforts in 2025.
With people at the heart of our One Lonza business, our People Strategy is built to ignite performance through agility in how we work, the capabilities we build, and the culture we create together. Looking ahead, we will continue to strengthen our talent pipeline by building a dynamic and adaptable workforce, investing in growth and excellence, and fostering a connected and inclusive environment where our people can thrive and bring their best.
In 2025, we enhanced our drug development and manufacturing offering. We upgraded our facilities in Visp, Portsmouth and Stein and achieved strong commercial momentum through operational excellence. We also continued to integrate Vacaville into our global network. These developments reflect our continuing dedication to turning breakthrough innovations into viable therapies for our customers and their patients.
In 2025, we maintained strong business momentum while aligning our portfolio to our strategic focus areas. We successfully ramped-up operations at our drug linker manufacturing plant and improved productivity at our bioconjugation suites in Visp, underlining our commitment to create long-term value for our customers. Additionally, we signed a large multi-year commercial supply agreement in our Small Molecules business, and made productivity gains across the Business Platform as part of our network optimization strategy.
We entered new partnerships and expanded our capabilities across Specialized Modalities in 2025. We launched two new commercial programs, gained GMP qualification for mRNA manufacturing in Geleen, launched several innovative products and expanded our testing solutions portfolio with the acquisition of Redberry SAS. These achievements underline our commitment to execution excellence, scalability, and collaboration to support customers from early development through to commercial supply.
2025 has been a year of positive change and momentum for CHI. We have refocused our efforts on our core business and successfully launched new Products such as our organic Organicaps™ capsule to address growing demand for organic and vegan supplements. Our drive for commercial excellence and productivity initiatives has delivered positive sales growth and expanded margins. As we prepare for our exit from Lonza, we look forward to a new chapter with confidence in our ability to continue to meet our customers’ needs.
